Study of ECC4703 With Sulfasalazine and Pitavastatin
Sponsor: Eccogene • ClinicalTrials.gov ID: NCT07726368
Recruiting for Similar Conditions?
Sponsors are looking for patients like you. See if you qualify for compensated research studies.
Check Eligibility →Description
Non-alcoholic fatty liver disease is a chronic, serious, life-threatening, inflammatory liver disease characterized by increased liver fat content, inflammation, and progressive fibrosis. The overall prevalence of non-alcoholic fatty liver disease is rapidly rising world-wide. ECC4703 is a potential new treatment for non-alcoholic fatty liver disease. The purpose of this research is to investigate the safety, tolerability and pharmacokinetics of sulfasalazine and pitavastatin when combined with ECC4703.
Interventions
-
ECC4703
(Drug)
ECC4703 will be administered orally.
-
Sulfasalazine
(Drug)
Sulfasalazine will be administered orally.
-
Pitavastatin
(Drug)
Pitavastatin will be administered orally.
Eligibility criteria
Conditions
Locations
- Nucleus Network Pty Ltd — Melbourne, Victoria, Australia
Partner with Nurenyx
Showcase your study to thousands of motivated patients matching your criteria.
Learn MoreOfficial Source
Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
View Official Record